Novartis: FDA approves use of Tasigna in pediatric patients
(CercleFinance.com) - The US Food and Drug Administration has approved the use of Novartis' Tasigna in pediatric patients aged at least 1 who have been newly diagnosed wtih Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.
Health regulators said the approval was based on results for 69 patients from two multi-center trials.
The median time on treatment was 13.8 months.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Health regulators said the approval was based on results for 69 patients from two multi-center trials.
The median time on treatment was 13.8 months.
Copyright (c) 2018 CercleFinance.com. All rights reserved.